

Special Issue

Current Trends and Advances in Spondyloarthritis

Message from the Guest Editor

Spondyloarthritis (SpA) represent a heterogeneous group of chronic inflammatory diseases, characterized by axial, enthesitis and peripheral involvement that may occur together with extra-articular manifestations. In recent years, although the growing knowledge of pathophysiology, genetic predisposition, classification criteria, imaging and treatment has profoundly increased the quality of the research on SpA, the complexity and variety of clinical manifestations of the disease still cause diagnostic and therapeutic delay. Thus, the increased awareness of the early stage of the disease and knowledge of clinical progression in late stages might contribute to revolutionize the treat-to-target strategy with more tailored and multifactorial treatments and the achievement of a drug-free remission in SpA patients. The aim of this Special Issue is to provide a broad update on the pathogenetic, diagnostic and clinical aspects of SpA that might ameliorate the knowledge from bench to bedside of some still enigmatic aspects of disease. We are soliciting original articles, reviews, systematic reviews and meta-analyses, as well as case series related to future challenges in the field of SpA.

Guest Editor

Dr. Francesca Bandinelli

Rheumatology Department, USL Tuscany Center, San Giovanni di Dio Hospital, Via di Torre Galli 3, 50143 Florence, Italy

Deadline for manuscript submissions

30 April 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/195160

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/jpm)

[jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).